While Suicide Remains A Leading Cause Of Death In The U.S., Depression Treatment Options Expand as Psychedelic-Assisted Therapy Proves to be an Increasingly Effective Approach to Transformative Mental Health
September 06, 2021 08:00 ET | Psychable, Inc.
This Suicide Prevention Week, Psychable Offers Comprehensive Information on Treatment Options and Safe Access to Practitioners Through Supportive Online Community LOS ANGELES, Sept. 06, 2021 ...
National Recovery Month: Interest in Psychedelic-Assisted Therapy to Treat Addiction Grows as Substance Abuse Skyrockets Amidst Backdrop of Pandemic
September 01, 2021 09:00 ET | Psychable, Inc.
Psychable Online Community Connects Those Seeking Treatment with Knowledgeable Psychedelic Professionals in a Trusted and Safe Space LOS ANGELES, Sept. 01, 2021 (GLOBE NEWSWIRE) -- With a...
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
August 19, 2021 08:17 ET | InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
August 16, 2021 07:00 ET | atai Life Sciences
-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as...
NEW ATAI-Logo_Primary.png
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
August 12, 2021 08:50 ET | atai Life Sciences
BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
August 06, 2021 18:10 ET | atai Life Sciences
BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
New poll shows a strong base of Canadians overwhelmingly support controlled legal access to psilocybin-assisted therapy; Canadian Psychedelic Association responds with Memorandum of Regulatory Approval (MORA)
August 04, 2021 07:02 ET | Canadian Psychedelic Association
Vancouver, BC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A Nanos Research Survey released today by the Canadian Psychedelic Association (CPA) shows 82 percent of Canadians approve the use of...
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 03, 2021 08:00 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
NEW ATAI-Logo_Primary.png
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
July 28, 2021 09:12 ET | atai Life Sciences
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the...
The Psychedelic Capital: July 2021 Conference Returns Seeks to Present Attendees With Insights Into the Latest Trends, Companies and Developments Within the Global Psychedelics Industry
July 22, 2021 10:07 ET | Microdose Psychedelic Insights
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging...